US 2008.00899.46A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/008994.6 A1 Olalde Rangel (43) Pub. Date: Apr. 17, 2008 (54) SYNERGISTIC PHYTOCEUTICAL A6IR 36/21 (2006.01) COMPOSITIONS A6IR 36/232 (2006.01) A6IR 36/258 (2006.01) (76) Inventor: Jose Angel Olalde Rangel, Caracas A6IR 36/28 (2006.01) (VE) A6IR 36/286 (2006.01) A6IR 36/3 (2006.01) Correspondence Address: A6IR 36/4I (2006.01) BAKER & MCKENZE LLP A6IR 36/45 (2006.01) Pennzoil Place, South Tower A6IR 36/48 (2006.01) 711 Louisiana, Suite 3400 A6IR 36/7 (2006.01) HOUSTON, TX 77002-2716 (US) A6IP 7/00 (2006.01) A6IP 5/00 (2006.01) (21) Appl. No.: 11/924,122 A6IP 9/00 (2006.01) (52) U.S. Cl. .................... 424/548; 424/195.15; 424/725: (22) Filed: Oct. 25, 2007 424/726; 424/728; 424/732: 424/737; 424/752; 424/755; Related U.S. Application Data 424/757; 424/773; 424/775 (62) Division of application No. 1 1/271,940, filed on Nov. (57) ABSTRACT 10, 2005, now Pat. No. 7,303,772. Phytoceutical compositions for the prevention and treatment Publication Classification of circulatory disorders, feminine endocrine disorders, and dermal disorders. A specific combination of extracts of (51) Int. Cl. plants is taught, as well as principles for varying the for A6 IK 36/00 (2006.01) mulations based on categorizing plants into one of three A6 IK 35/32 (2006.01) groups, Energy, Bio-Intelligence, and Organization and A6 IK 36/074 (2006.01) selecting several plants from each group. Such combinations A6 IK 36/16 (2006.01) have synergistic effects, with minimal side effects. Patent Application Publication Apr. 17, 2008 Sheet 1 of 3 US 2008/008994.6 A1 Figars f: Fatigraphie sewidiaries of iaitetic Fest rismissics, irreiading isfigth of treatnessert sefree phasis. ? Doppier titrestand fe Patent Application Publication Apr. 17, 2008 Sheet 2 of 3 US 2008/008994.6 A1 figure 2: Pts -before w after eitasaragrapefic carparison. Afterwal fetween echesonagranrass if trantis SSSSSS SS 87. Patent Application Publication Apr. 17, 2008 Sheet 3 of 3 US 2008/008994.6 A1 Figure 3: Photographic eviderace of severe Psoriasis remissions, including length of treatner between photos US 2008/008994.6 A1 Apr. 17, 2008 SYNERGISTIC PHYTOCEUTICAL Polycystic Ovary Syndrome, ovarian cysts, fibrocystic COMPOSITIONS breast condition, uterine fibroids, dysfunctional uterine hem orrhage, female infertility, premenstrual syndrome, amenor PRIOR RELATED APPLICATIONS rhea, and the like. 0001. Not applicable. 0009. Another embodiment of the invention provides a composition for chronic skin disorders. It can be used alone FEDERALLY SPONSORED RESEARCH or combined with pharmaceuticals, and can be used to treat STATEMENT diseases such as psoriasis, dermatitis, skin infections, 0002) Not applicable. shingles (herpes Zoster), boils, eczema, rash, acne or burn, and the like. REFERENCE TO MICROFICHEAPPENDIX 0003) Not applicable. DETAILED DESCRIPTION OF THE FIGURES 0010 FIG. 1 shows representative examples of diabetic FIELD OF THE INVENTION foot lesions treated with the herbaria of Table 1. 0004 The invention relates to phytoceutical formulations 0011 FIG. 2 shows representative examples of PCOS used to treat a variety of diseases. The formulations are treated with the herbaria of Table 2. particular combinations of plants and have synergistic effect in combination. Principles for selecting beneficial formula 0012 FIG. 3 shows representative examples of psoriasis tions are provided. treated with the herbaria of Table 3. BACKGROUND OF THE INVENTION DETAILED DESCRIPTION OF THE 0005 The academic study of medicinal plants for the INVENTION treatment of diverse diseases has been nearly as pervasive as 0013 “Pharmaceutically acceptable excipients’ is used the study of Western medicines—The active principles from herein according to art accepted meanings, and includes many traditional medicines have been extracted from plants, those ingredients needed to formulate a medicine for mam the curative agents identified and their mechanisms of action malian use, including the use of gelatin capsules. determined. Plant based medicines are typically well toler ated, with less severe side effects as well as a Smaller range 0014 “Synergistic' or “synergy” is used herein to mean of side effects. However, despite the excellent medicinal that the effect is more than its additive property. In preferred qualities of many plants, they are individually insufficient to embodiments, the synergy is at least 1.5, 2, 5, or 10 fold. take chronic degenerative diseases into remission. In con 0015. By use of “plants,” what is meant herein is that the trast, while synthetic drugs can be highly effective, their use plant (or that portion with medicinal activity) is used whole, is often hampered by severe side effects. What is needed in ground, or as an extract. Also included are purified active the art are better treatment regimes with improved patient ingredients and derivatives thereof. However, it is believed tolerance, while providing Sufficient efficacy. that the best efficacy of plants used herein is achieved with the use of the entire plant or its extracts, rather than with the SUMMARY OF THE INVENTION use of isolated active ingredients. 0006. A number of known beneficial plants were classi fied according to their capacity to enhance the three main 0016 Further, although plants are named here according elements that support overall health: Energy (E), Bio-intel to commonly used nomenclature, with improving taxonomy ligence (I) and Organization (O). A synergistic effect is plants are often reclassified. Whenever a plant is referenced, expected when all three categories of herbs (E. I. O) are it includes related species with similar active ingredients. included in a formulation, preferably at least two or three or 0017. The following examples are illustrative only and four plants from each category. Thus, one embodiment of the should not serve to unduly limit the invention. invention provides a method of selecting additional disease treating formulations according to these principles. Three EXAMPLE 1. examples of formulations prepared in this way are provided and additional formulations are being prepared and tested. Plant Characteristics Circulatory Disorders 0007 Another embodiment of the invention provides an 0018 Angelica sinensis (Dong Quai or Angelica, also effective, natural composition for treating circulatory dis Angelica Archangelia, Angelica Pubescens and Angelica eases. The composition can be used alone, or can be com Sylvestris) contains terpenes (terpenes, mainly B-phelland bined with simultaneous use of one or more pharmaceutical rene, with B-bisabolene, B-caryophyllene, B-phellandrene, compositions. It can be used for the treatment of diabetic C- and B-pinene, limonene, linalool, borneol, acetaldehyde, lesions, obliterative arteriosclerosis, Leriche Syndrome menthadienes, and nitromenthadienes), macrocyclic lac (aorto-iliac obliteration), Buerger's disease (thromboangiitis tones (including tridecanolide, 12-methyl tridecanolide, obliterans), thrombophlebitis, chronic venous insufficiency, pentadecanolide), phthalates (such as hexamethylphthalate), Varicose veins, varicose ulcers, hemorrhoids, and the like. coumarins (especially flirocoumarin glycosides Such as 0008 Another embodiment of the invention provides a marmesin and apterin), angelicin and byakangelicin deriva composition for the treatment of feminine endocrine dis tives (osthol, umbelliferone, psoralen, bergapten, impera eases that can be used alone or combined with pharmaceu toren, XanthotoXol, Xanthotoxin, oxypeucedanin and more), ticals. It provides an effective medicine for diseases such as as well as various Sugars, plant acids, flavonoids, and sterols. US 2008/008994.6 A1 Apr. 17, 2008 0.019 Acanthopanax senticosus (Russian Ginseng, Sibe of c(GMP and cAMP levels and prolongation of the time rian Ginseng, Eleuthero, Devil's Shrub, Touch-me-not, Wild interval between the conversion of fibrinogen to fibrin. Pepper, Shigoka, Acantopanacis senticosus) contains terpe Ginsenosides have also been shown to be relatively potent noids (oleanolic acid), glycosides (Eleutheroside A (daucos platelet activating factor antagonists. It has antioxidant, terin), B1, C-G, I, K, L, M), phytosterols (B-sitosterol), anti-inflammatory, and hypolipidemic effects. The incorpo coumarins (Eleutheroside B1 and B3, isofraxidine), polysac ration of this phytomedicine into a composition provides at charides (eleutherans), volatile oils, caffeic acid, coniferyl least 206 active principles in a single therapeutic. aldehyde, and sugars. Eleuthero has been shown to bind to estrogen, progestin, and mineralocorticoid receptors, and 0023 Pfaffia paniculata (Suma, Brazilian Ginseng, Pfaf stimulate T-lymphocyte and natural killer cell production. It fia, Para Toda, Corango-acu; also Hebanthe paniculata, has activity anti-platelet aggregation activity similar to aspi Gomphrena paniculata, G. eriantha, Iresine erianthos, I. rin, as well as antioxidant activity. Russian Ginseng contains paniculata, I. tenuis, P. eriantha, Xeraea paniculata) con at least 40 active ingredients. tains active glycosides (beta-ecdysone and three ecdys teroids), pfaffic acids, phytosterols (sitosterol and estimas 0020 Rhaponticum carthamoides (Leuzea, or Maral terol). It also contains Saponins. Its germanium content Root) contains a mixture of compounds called, “levseins.” probably accounts for its properties as an oxygenator at the Levseins represents a complex of more than 10 ecdysterones cellular level,